BRIDGEBIO ONCOLOGY THERAPEUT BBOT
COM NEW · Common Stock · CUSIP 107924102
- SectorHealth care
- IndustryPharmaceutical Preparations
- HeadquartersSouth San Francisco, CA
- FilingsSEC EDGAR
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $11.57.
Biggest buyers
| Cormorant Asset Management, LP | New | +17.9m |
| DEERFIELD MANAGEMENT COMPANY, L.P. | New | +4.9m |
| Omega Fund Management, LLC | New | +3.3m |
| WELLINGTON MANAGEMENT GROUP LLP | New | +3.0m |
| EcoR1 Capital, LLC | New | +2.8m |
| Alphabet Inc. | New | +2.8m |
| ENAVATE SCIENCES GP, LLC | New | +2.6m |
| CITADEL ADVISORS LLC | New | +2.5m |
| BlackRock, Inc. | New | +2.0m |
| NOVO HOLDINGS A/S | New | +2.0m |
Biggest sellers
| None |
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
Helix Holdings II LLC
13D · may seek influence
filed 2025-08-13
Stated purposeItem 4 is hereby amended and supplemented as follows: As previously disclosed, on February 28, 2025, the Issuer (which was formerly known as Helix Acquisition Corp. II, "Helix") entered into a Business Combination Agreement (as amended on June 20, 2025, the "Business Combination Agreement") with TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics, "Legacy BBOT"), and Helix II Merger Sub, Inc. ("Merger Sub"), pursuant to which, subject to the satisfaction or waiver of certain conditions set forth therein, the Domestication of Helix as a Delaware corporation would occur, followed by the Merger of Merger Sub with and into Legacy BBOT. Prior to the Business Combination, Ms. Chen was the Chairwoman and Chief Executive Officer of the Issuer, a shareholder of the Issuer, and a shareholder of Leg… Full filing |
22.6% |
Chen Bihua
13D · may seek influence
filed 2026-07-06
Stated purposeItem 4 is hereby amended and supplemented as follows: On July 1, 2026, Sponsor distributed 4,528,186 shares of Common Stock, pro rata, to its members for no consideration. Following such transaction, Sponsor holds no shares of Common Stock. As a result of Sponsor's pro rata distribution of shares to its members, (i) Fund III, a member of Sponsor, acquired 2,692,459 shares of Common Stock; (ii) Fund V, a member of Sponsor, acquired 1,704,862 shares of Common Stock; and (iii) Master Fund, a member of Sponsor, acquired 130,865 shares of Common Stock. Full filing |
22.3% |
BridgeBio Pharma LLC
13D · may seek influence
new · filed 2025-08-18
Stated purposeThe Reporting Persons acquired the Shares for investment purposes in the ordinary course of business. Immediately following the Effective Time of the Business Combination, Neil Kumar, Ph.D., Chief Executive Officer and a member of the board of directors of BBIO, and Frank P. McCormick, Ph.D., F.R.S., D.Sc., Chairman of Oncology and a member of the board of directors of BBIO, were appointed to serve as directors of the Issuer. As a result of their positions, Drs. Kumar and McCormick may, from time to time, engage in discussions with the Issuer's board of directors, management, or other stockholders regarding matters relating to the Issuer's business, operations, governance, strategy, or capital structure. These discussions may include, but are not limited to: (i) the acquisition or dispos… Full filing |
17.5% |
| BlackRock Portfolio Management LLC 13G · institution new · filed 2025-04-15 | 7.9% |
| Flynn James E 13G · passive investor new · filed 2025-08-18 | 6.2% |
| BC Global Opportunities IX LP 13G · passive investor new · filed 2025-09-03 | 5.5% |
Insider purchases and sales in Q3 2025
Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.
Officers and directors buying vs selling
Number of people, by quarter (10% owners not included)
Numbers
| Quarter | Buying | Bought | Selling | Sold | Sold under a plan |
|---|---|---|---|---|---|
| Q4 2023 | 0 | — | 0 | — | — |
| Q1 2024 | 1 | $24.0m | 0 | — | — |
| Q2 2024 | 0 | — | 0 | — | — |
| Q3 2024 | 0 | — | 0 | — | — |
| Q4 2024 | 0 | — | 0 | — | — |
| Q1 2025 | 0 | — | 0 | — | — |
| Q2 2025 | 0 | — | 0 | — | — |
| Q3 2025 | 0 | — | 0 | — | — |
None reported in Q3 2025.
Holders, Q3 2025
| Manager | Shares | Change |
|---|---|---|
| Cormorant Asset Management, LP 14.29% of their portfolio | 17.9m $207.0m | New |
| DEERFIELD MANAGEMENT COMPANY, L.P. 0.87% of their portfolio | 4.9m $56.6m | New |
| Omega Fund Management, LLC 17.13% of their portfolio | 3.3m $38.1m | New |
| WELLINGTON MANAGEMENT GROUP LLP 0.01% of their portfolio | 3.0m $34.3m | New |
| EcoR1 Capital, LLC 1.57% of their portfolio | 2.8m $32.7m | New |
| Alphabet Inc. 1.36% of their portfolio | 2.8m $32.7m | New |
| ENAVATE SCIENCES GP, LLC 9.29% of their portfolio | 2.6m $30.4m | New |
| CITADEL ADVISORS LLC 0.02% of their portfolio | 2.5m $29.4m | New |
| BlackRock, Inc. 0.00% of their portfolio | 2.0m $23.7m | New |
| NOVO HOLDINGS A/S 1.46% of their portfolio | 2.0m $22.7m | New |
| Paradigm Biocapital Advisors LP 0.64% of their portfolio | 1.9m $21.6m | New |
| ADAGE CAPITAL PARTNERS GP, L.L.C. 0.03% of their portfolio | 1.5m $17.2m | New |
| EVENTIDE ASSET MANAGEMENT, LLC 0.20% of their portfolio | 1.1m $12.4m | New |
| Laurion Capital Management LP 1.65% of their portfolio | 1.0m $12.1m | New |
| Octagon Capital Advisors LP 1.89% of their portfolio | 1.0m $12.1m | New |
| PRICE T ROWE ASSOCIATES INC /MD/ 0.00% of their portfolio | 885.0k $10.2m | New |
| VANGUARD GROUP INC 0.00% of their portfolio | 647.6k $7.5m | New |
| Aisling Capital Management LP 1.43% of their portfolio | 564.6k $6.5m | New |
| GEODE CAPITAL MANAGEMENT, LLC 0.00% of their portfolio | 541.6k $6.3m | New |
| ADAR1 Capital Management, LLC 0.57% of their portfolio | 501.2k $5.8m | New |
| SILVERARC CAPITAL MANAGEMENT, LLC 0.77% of their portfolio | 457.4k $5.3m | New |
| ARMISTICE CAPITAL, LLC 0.15% of their portfolio | 412.0k $4.8m | New |
| MILLENNIUM MANAGEMENT LLC 0.00% of their portfolio | 369.6k $4.1m | New |
| Casdin Capital, LLC 0.27% of their portfolio | 282.3k $3.3m | New |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.00% of their portfolio | 279.4k $3.2m | New |
| Ikarian Capital, LLC 0.57% of their portfolio | 245.2k $2.8m | New |
| STEMPOINT CAPITAL LP 0.44% of their portfolio | 186.6k $2.2m | New |
| STATE STREET CORP 0.00% of their portfolio | 176.7k $2.0m | New |
| FMR LLC 0.00% of their portfolio | 162.1k $1.9m | New |
| Sio Capital Management, LLC 0.38% of their portfolio | 130.6k $1.5m | New |
| TD Asset Management Inc 0.00% of their portfolio | 130.1k $1.5m | New |
| Woodline Partners LP 0.01% of their portfolio | 103.7k $1.2m | New |
| MOORE CAPITAL MANAGEMENT, LP 0.02% of their portfolio | 100.0k $1.2m | New |
| BOOTHBAY FUND MANAGEMENT, LLC 0.03% of their portfolio | 96.6k $1.1m | New |
| NORTHERN TRUST CORP 0.00% of their portfolio | 96.0k $1.1m | New |
| UBS Group AG 0.00% of their portfolio | 52.2k $604.8k | New |
| XTX Topco Ltd 0.01% of their portfolio | 23.4k $270.8k | New |
| China Universal Asset Management Co., Ltd. 0.00% of their portfolio | 5.0k $57.9k | New |
| BANK OF AMERICA CORP /DE/ 0.00% of their portfolio | 1.3k $15.4k | New |
| MORGAN STANLEY 0.00% of their portfolio | 861 $10.0k | New |
| FNY Investment Advisers, LLC 0.00% of their portfolio | 100 $1.0k | New |
| ROYAL BANK OF CANADA 0.00% of their portfolio | 16 $0 | New |